Sign up to create alerts for Instruments,
Economic Events and content by followed authors
Free Sign Up Already have an account? Sign In
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Quotes
All Instrument Types
- All Instrument Types
- Indices
- Equities
- ETFs
- Funds
- Commodities
- Currencies
- Crypto
- Bonds
- Certificates
Please try another search
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details
Sanofi and Regeneron cut list price of cholesterol drug by 60 percent
© Reuters. FILE PHOTO: The logo of Sanofi is pictured during the Viva Tech start-up and technology summit in Paris
By Michael Erman
NEW YORK (Reuters) - Sanofi (PA:SASY) SA and Regeneron Pharmaceuticals Inc (NASDAQ:REGN) said on Monday that they will slash the U.S. list price of their potent but expensive cholesterol fighter Praluent by 60 percent, as the drugmakers follow a similar move by rival Amgen Inc (NASDAQ:AMGN) in hopes of increasing use of the drug.
The new list price for Praluent will be $5,850 a year, matching the price Amgen set when it lowered the list of its competing drug, Repatha, in October.
Sanofi and Regeneron said they expect the lower-priced Praluent to be available for pharmacies to order in early March. They said the new price should improve patient access and result in lower out-of-pocket costs for U.S. consumers.
Praluent and Repatha belong a class of injectable biotech drugs called PCSK9 inhibitors that dramatically lower bad LDL cholesterol and reduce the risk of heart attacks and death.
Sales of both have been severely constrained by onerous roadblocks to patient access put up by insurers looking to limit spending on the expensive drugs.
They were approved in 2015 with initial list prices of more than $14,000 a year.
In March of last year, Regeneron and Sanofi said that they would be willing to charge less for their drug if insurers agreed to reduce barriers for high-risk heart patients.
A few months later they struck a deal with Express Scripts (NASDAQ:ESRX), now part of Cigna Corp (NYSE:CI), to make the drug available to that company's customers at a price in the range of $4,500 to $6,600 a year.
The United States, which leaves drug pricing to market competition, has higher prices than in other developed countries, where governments directly or indirectly control costs. That makes it by far the world's most lucrative market for manufacturers.
Congress has been targeting the pharmaceutical industry over the rising cost of prescription drugs for U.S. consumers, particularly since Democrats took over the House of Representatives in January.
Executives from at least six drugmakers plan to testify at a Senate hearing on rising prescription drug prices later this month.
Drug pricing is also a top priority of the administration of President Donald Trump, who had made it a central issue of the 2016 presidential campaign.
Related Articles
Siemens Energy launches $4.3 billion bid for remaining Siemens Gamesa stake
By Reuters - May 21, 2022
By Ludwig Burger and Christoph Steitz FRANKFURT (Reuters) -Siemens Energy on Saturday launched a 4.05 billion euro ($4.28 billion) bid for the remaining shares in struggling wind...
Biden says first shipments of baby formula flying in from Europe this weekend
By Reuters - May 21, 2022
28
(Reuters) - The first shipments of infant formula from Europe to address a critical shortage in the United States should begin arriving this weekend, President Joe Biden said on...
HSBC banker's remarks on climate risk inconsistent with strategy, CEO says
By Reuters - May 21, 2022
7
(Reuters) - HSBC Holdings (NYSE:HSBC) CEO Noel Quinn says his bank will not be distracted from its ambition to lead the global economy in the transition to net zero, after a...
Add Chart to Comment
Confirm Block
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
Report this comment
I feel that this comment is:
Comment flagged
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.